JPMorgan Chase & Co. Cuts Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $199.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective decreased by JPMorgan Chase & Co. from $204.00 to $199.00 in a research note issued to investors on Monday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the specialty pharmaceutical company’s stock.

A number of other analysts have also recently weighed in on JAZZ. Morgan Stanley set a $183.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, October 24th. Weiss Ratings restated a “sell (d)” rating on shares of Jazz Pharmaceuticals in a report on Wednesday, October 8th. Wells Fargo & Company set a $170.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, October 22nd. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Jazz Pharmaceuticals in a report on Tuesday, July 15th. They issued a “buy” rating and a $152.00 price target on the stock. Finally, Truist Financial raised their price target on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a “buy” rating in a report on Thursday, August 28th. Fourteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $179.33.

Jazz Pharmaceuticals Trading Down 1.7%

NASDAQ JAZZ opened at $135.73 on Monday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. The company has a market capitalization of $8.23 billion, a price-to-earnings ratio of -20.17, a price-to-earnings-growth ratio of 8.81 and a beta of 0.28. The company’s 50-day simple moving average is $131.59 and its two-hundred day simple moving average is $117.75. Jazz Pharmaceuticals has a one year low of $95.49 and a one year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing analysts’ consensus estimates of ($5.61) by ($2.64). The business had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same period last year, the business posted $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Equities analysts forecast that Jazz Pharmaceuticals will post 16.96 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Bruce C. Cozadd sold 3,500 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $140.00, for a total value of $490,000.00. Following the completion of the sale, the director directly owned 408,826 shares in the company, valued at $57,235,640. This trade represents a 0.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last ninety days, insiders have sold 11,500 shares of company stock valued at $1,525,280. 4.30% of the stock is owned by company insiders.

Institutional Trading of Jazz Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Philip James Wealth Mangement LLC lifted its stake in Jazz Pharmaceuticals by 42.0% during the 2nd quarter. Philip James Wealth Mangement LLC now owns 15,797 shares of the specialty pharmaceutical company’s stock valued at $1,676,000 after acquiring an additional 4,675 shares during the period. State of Alaska Department of Revenue lifted its stake in Jazz Pharmaceuticals by 75.1% during the 2nd quarter. State of Alaska Department of Revenue now owns 57,933 shares of the specialty pharmaceutical company’s stock valued at $6,147,000 after acquiring an additional 24,850 shares during the period. Inspire Investing LLC acquired a new stake in Jazz Pharmaceuticals during the 1st quarter valued at approximately $689,000. Baird Financial Group Inc. acquired a new stake in Jazz Pharmaceuticals during the 1st quarter valued at approximately $539,000. Finally, Voya Investment Management LLC lifted its stake in Jazz Pharmaceuticals by 67.1% during the 1st quarter. Voya Investment Management LLC now owns 56,349 shares of the specialty pharmaceutical company’s stock valued at $6,996,000 after acquiring an additional 22,628 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.